A Prognostic Signature for Lung Adenocarcinoma in Patients Who Have Never Smoked

Zhao W.; Zhang T.; Hua X.; Hoang P.H.; Miraftab M.; Saha M.; McElderry J.P.; Sang J.; Lee O.W.; Hartman C.; Khandekar A.; Sharma S.; Colón-Matos F.J.; Anyaso-Samuel S.; Wang D.; Jones K.; Hutchinson A.; Hicks B.; Rosenbaum J.; Zhong X.; Yang Y.; Pesatori A.C.; Consonni D.; Christiani D.C.; Leung K.C.; Wong M.P.; Manczuk M.; Lissowska J.; Świątkowska B.; Mukeria A.; Shangina O.; Zaridze D.; Holcatova I.; Mates D.; Milosavljevic S.; Ognjanovic S.; Savic M.; Kontic M.; Gaborieau V.; Brennan P.; Arrieta O.; Bossé Y.; Edell E.S.; Schabath M.B.; Hofman P.; Mas L.; Yendamuri S.S.; Chen C.-Y.; Chang I.-S.; Hsiung C.A.; Liu G.; Santamaría J.M.; Rothberg B.E.G.; Mutreja K.; Lawrence S.; Rothman N.; Alexandrov L.B.; Leduc C.; Baine M.K.; Joubert P.; Sholl L.M.; Travis W.D.; Homer R.; Lan Q.; Chanock S.J.; Yang L.; Yang S.-R.; Shi J.; Landi M.T. · Cancer Discovery (2026) · DOI: 10.1158/2159-8290.cd-25-0581

Resumen

Understanding tumor cell dynamics can improve prognosis and treatment but remains limited for lung adenocarcinoma in people who have never smoked (NS-LUAD). With RNA sequencing data from 684 NS-LUAD cases and validation in an independent dataset, we identified three subtypes with distinct phenotypic traits and cell compositions. Additional genomic and histologic data further characterized the subtypes. “Steady,” marked by low proliferation, high alveolar cell fraction, moderate-to-well differentiation, and fewer driver gene alterations, is linked to prolonged survival and low immune evasion. “Proliferative” shows high proliferation markers, TP53 mutations, and gene fusions. “Chaotic,” with high epithelial-to-mesenchymal transition markers, has the worst prognosis, even within stage I tumors. Lacking known molecular or histologic characteristics, this aggressive subtype is solely identified by transcriptomic data. A 60-gene signature recapitulates the classification and predicts survival even within subgroups based on tumor stage or known genomic features, emphasizing its potential for improving early-stage NS-LUAD prognostication in clinical settings. Significance: The transcriptome of 684 NS-LUAD identifies three subtypes with different cellular dynamics and genomic and morphologic features. A 60-gene signature accurately stratifies subjects for mortality risk, even in stage I, offering a potential clinically applicable tool for treatment decision-making in patients with NS-LUAD.